We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior

News   Sep 07, 2015

 
Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior
 
 
 

RELATED ARTICLES

Patent Issued for Osteoarthritis Gene Therapy Product

News

A potentially disease-modifying therapy for osteoarthritis has reached a key milestone now that a U.S. patent has been issued for FX201, a gene-therapy product candidate based on work led by Baylor College of Medicine researchers.

READ MORE

Stage Set for Uncovering Multiple Autoimmune Drug Targets

News

The identification of molecular signatures that reflect the pathology of lupus and arthritis provide new insights into tissue damage, and set the stage for uncovering potential drug target candidates.

READ MORE

Targeting High-speed Cell Division in Cancer Cells

News

In malignant tumors, the cells usually proliferate quickly and uncontrollably. Researchers have discovered that two important regulators of cell division can interact in this process. If this is the case, affected patients have particularly poor chances of survival. The long-term goal is to suppress tumor growth by blocking the interaction.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE